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Abstract
Background: In Germany, medical care of prisoners is completely separated from extramural health care. The
extent and quality of medical care among prisoners in Germany are therefore largely unknown. We performed a
secondary data analysis of pharmacy sales data for tuberculosis (TB), HIV, hepatitis C (HCV) and opioid substitution
treatment (OST) delivered to prisons in 11 federal states (FS) in Germany between 01/2012 and 03/2013. The aims
of this study were to assess (i) the treatment availability for the selected diseases and OST in German prisons, (ii)
the proportion of prisoners treated per FS and overall for TB, HIV, HCV and OST during the study period.
Methods: Substances unique to or typically used for the treatment of each disease were defined as marker
substances with defined daily doses (DDD).
For each marker substance we assessed the cumulative number of DDD, the average daily number of DDD (DDDd)
and average treatment prevalence per day in percent (adTP). Accordingly, the DDDd represents one person treated
per day and the adTP means the proportion of prisoners treated per day. We compared the adTP of the diseases
with previously measured prevalences.
Results: We obtained data from pharmacies supplying prisons in 11 of 16 German FS. Of the included prisons, 41%
were supplied with medicines for TB, 71% for HIV and 58% for HCV and OST. Twice as many delivered marker
substances for TB were indicated for the continuation phase and chemoprevention than the intensive phase. The
HIV adTP ranged from 0.06% to 0.94%, HCV adTP ranged from 0.03% to 0.59% and OST adTP ranged from 0% to 7.
90%. The overall adTP for the respective treatment was 0.39% for HIV, 0.12% for HCV and 2.18% for OST.
Conclusions: According to our findings treatment rates for TB were consistent with the expected TB prevalence, at
least in Berlin. HIV treatment seems to be offered to an adequate proportion of estimated infected prisoners. In
contrast, the HCV treatment prevalence was low. High variation among FS in provision of all treatments, particularly of
OST, point to inconsistent treatment practices, although nationwide extramural treatment guidelines for Germany exist.
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Background
Studies have shown that specific blood- and air-borne
and sexually transmitted infections are more common
among prisoners than in the general population: in
Germany and other European countries, tuberculosis
(TB) prevalence was 11 to 81 times higher, hepatitis C
virus (HCV) prevalence was 17 to 100 times higher,
human immunodeficiency virus (HIV) prevalence was 5
to 24 times higher and opioid dependence was 70 times
higher among prisoners in comparison to the general
population [1–8]. TB is primarily an airborne disease
and the bacteria are usually spread from person to per-
son through infectious droplet nuclei when an infectious
pulmonary TB patient coughs or sneezes [9]. Usually, a
prolonged and close contact is required for transmission;
therefore the prison setting can facilitate the spread of
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the disease. HIV and HCV can be transmitted via unpro-
tected sexual contacts as well as through the widespread
intramural practice of unsafe drug use and tattooing in-
volving the sharing of potentially infectious needles, sy-
ringes and other paraphernalia [8, 10–16]. Thus
transmission risks and infection events are highly in-
creased in prisons, especially due to the absence of ster-
ile drug injecting utensils and restricted access to
condoms and other prevention measures.
Nevertheless, the prison setting presents not only chal-
lenges, but also opportunities for the prevention and
treatment of TB, HIV and hepatitis [17]. Prevention of
HIV and HCV by offering testing and counselling, pro-
viding condoms and tattooing materials as well as sterile
injection equipment for people who inject drugs (PWID)
also includes the initiation and continuation of opioid
substitution treatment (OST) to reduce injection fre-
quency. Furthermore, the treatment of newly diagnosed
and already known infections is important not only for
the person infected but also in terms of treatment as
prevention [6, 18–23]. Despite various challenges in pro-
viding treatment for the mentioned infectious diseases
and offering OST in the prison setting, it is practicable,
and crucial to reduce transmission within prisons.
Different screening approaches exist to identify infec-
tions in prisons; however, systematic screening for infec-
tious diseases is not implemented in the German prison
system. Strategies differ among federal states (FS) and
singular prisons. TB screening by chest x-ray is
performed systematically on all prisoners at entrance in
the FS of Berlin [24], and in some other prisons, but in
most FS, symptom-based screening strategies are imple-
mented. Screening for sexually transmitted and blood-
borne viruses is also diverse, and ranges from test offer
to persons with clinical symptoms or risk factors,
request by the prisoner to mandatory testing in some
prisons or FS [5].
In Germany, treatment guidelines and effective treat-
ment regimens for TB, HIV and HCV as well as OST are
available [25–29], and all mentioned treatments are being
carried out among patients with statutory health insurance
(SHI) extramurally. Upon incarceration SHI is suspended,
and health care is provided and paid for by the federal
Ministry of Justice (MoJ) of the respective FS. As a result
of this transitional period between health care providers
treatment interruptions may occur [14, 30].
During the study period from January 2012 to March
2013, 67.607 people were detained in 186 prisons in the 16
FS of Germany [31], corresponding to nearly 0.08% of the
total German population. Throughout the study period, five
pharmacies supplied all prison hospitals and prisons in
Germany with pharmaceuticals. Implementation and
provision of health care lays within the responsibility of the
MoJ of the respective FS [32]. Nevertheless, according to
national laws (Prison Act § 56ff StVollzG; Social Act SGB
V), health care in the penitentiary system should take place
under the principle of equivalence of care and within the
standards of the SHI [14, 33]. Health care is implemented
by the prison doctor with the help of the prison administra-
tion, both of whom are under the supervision and directives
of the FS [14, 34, 35]. Medical care of prisoners is provided
by the prison doctor in out-patient care, in special prison
wards and correctional hospitals or wherever necessary by
extramural specialized medical doctors or hospitals [14].
Since not every prison has a sick ward and only some FS
have prison hospitals, contracts and transfer co-operations
exist among the states in order to ensure medical care in
every FS [34, 36–38].
Because prison health care is not part of the regular
public health system in Germany, it is therefore not part
of the health reporting system [14]. The extent and qual-
ity of TB, HIV, HCV and opioid dependence treatment
provided to prisoners in Germany are therefore largely
unknown [5, 6, 39].
In order to determine the medical care of infectious
diseases and opioid dependence among prisoners in
Germany we performed a secondary data analysis of
pharmacy sales data for TB, HIV, HCV treatments and
OST delivered to prisons in 11 FS in Germany between
January 2012 and March 2013. The aims of this study
were to assess (i) the treatment availability for the
selected diseases and OST in German prisons (ii) the
proportion of prisoners treated per FS and overall for
TB, HIV, HCV and OST during the study period.
Methods
We asked the MoJ of all 16 FS in Germany to approve
and support the planned data collection and analysis for
each respective FS in August 2013. Twelve FS agreed to
participate in the study; however, one FS was excluded
because the respective pharmacy did not provide the
data. In the participating FS, all prisons and prisoners of
the respective FS were included except one sick ward (5
beds) and one correctional hospital (52 beds) because
they were not supplied by one of the contract pharma-
cies. Throughout the study period, all participating
prisons and prison hospitals were supplied by three
pharmacies with TB, HIV, HCV and OST medicines.
The pharmacies provided the data for the period from
01/2012 to 03/2013. The dataset contained a minimum
of eight variables: the name of the prison, the FS, the
trade name of the drug, package size, dosage form, the
Anatomical Therapeutic Chemical (ATC) classification
code of the drug, the central pharmaceutical number
(Pharmazentralnummer, PZN), and the number of drug
packages supplied per month. The study collected solely
prescription data and no individual patient data. No
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ethical or data protection concerns were raised. The
names of the prisons were pseudonymized.
Substances unique to or typically used for the treat-
ment of each disease were defined as marker substances
for the respective disease. We used defined daily doses
(DDD) of the marker substances to calculate the number
of daily treated persons. The DDD were determined
based on current national treatment guidelines, prescrib-
ing information according to the German Medicines Act
and literature research (Table 1). The number of stand-
ard units (e.g. tablets, pens) was determined for each
marker substance.
First, we assessed the cumulative number of DDD
(DDDcum) of the marker substances for the whole study
period (456 days). Then we calculated the average daily
number of DDD for each marker substance for the study
period (DDDd). Accordingly the DDDd represents one
person treated with the respective substance per study
day. Finally, we calculated the average treatment preva-
lence per day in percent (average daily treatment preva-
lence, adTP). Accordingly, the adTP means the proportion
of prisoners treated per day with the respective drug to
the average number of all prisoners during the study
period (Fig. 1). We compared the adTP with previously
measured prevalences.
The number of incarcerated persons was obtained
from the German Federal Statistical Office, which pro-
vides this data in March, August and November each
year [31]. Based on these data an average monthly num-
ber of prisoners for the months of March 2012, August
2012, November 2012 and March 2013 were calculated
for each participating FS and for all participating states
in total (Fig. 2).
TB treatment
A standard six month treatment regimen for TB consists
of the four antitubercular substances ethambutol (E),
pyrazinamid (Z), isoniazid (H) and rifampicin (R).
Patients receive all four drugs daily for the first two
months (intensive phase), followed by H and R daily for
another four months (continuation phase). The marker
substances for anti-TB standard treatment were deter-
mined to be E, Z, H and R. The determined DDD were
1200 mg for E, 1500 mg for Z, 300 mg for H (except for
the formulation 400 mg per pill) and 600 mg for R as
recommended in the ATC classification (Table 1). The
standard regimen for latent tuberculosis infection (che-
moprevention) consists of either (i) H alone or (ii) a
combination of H and R or (iii) R alone [26]. For chemo-
prevention the marker substances were determined to
be H (DDD 300 mg) and/or R (DDD 600 mg). R and H
fixed-dose combinations were divided into single sub-
stances. Pyridoxin as an additive to H was not taken into
account. For multidrug-resistant-TB (MDR-TB), protio-
namide (Pto) and terizidone (Trd) were determined to
be the marker substances with a DDD of 750 mg. For
HIV-TB-coinfection the marker substance was rifabutin
(Rfb) with a DDD of 150 mg (Table 1).
HIV treatment
The standard therapy for HIV during the study period
contained exactly one thiacytidine medication (TCM),
Table 1 Marker substances and DDD
Disease Marker substances DDD [mg]
Tuberculosis [26, 58] Ethambutol (E) 1200
Pyrazinamid (Z) 1500





Hepatitis C [27, 58–60] Pegylated interferon-α (PEG-INF) 0.05, 0.08, 0.1, 0.12, 0.135, 0.15, 0.18
Boceprevir (BOC) 2400
Telaprevir (TVR) 2250
HIV [25, 58] Emtricitabin (FTC) 200
Lamivudin (3TC) 300




aFor the formulation of 400 mg isoniazid per pill the determined DDD was 400 mg
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either lamivudine (3TC) or emtricitabine (FTC). The
marker substances for HIV treatment were determined
to be 3TC and FTC (Table 1) [25, 40, 41]. The deter-
mined DDD were 300 mg for 3TC and 200 mg for FTC.
Drugs with more than one substance were split into sin-
gle substances.
HCV treatment
The standard therapy for HCV during the study period
consisted of peginterferon α-2a (PEG-IFN α-2a) or pegin-
terferon α-2b (PEG-IFN α-2b) in combination with ribavi-
rin (RBV). Furthermore, during the study period a triple-
therapy with the substances boceprevir (BOC) or telapre-
vir (TVR) in combination with PEG-IFN and RBV was
available. The marker substances for HCV treatment were
determined to be PEG-IFN α-2a, PEG-IFN α-2b, BOC
and TVR. We assumed that one pen PEG-IFN correlated
with one treated person. The determined DDD were
2400 mg for BOC and 2250 mg for TVR (Table 1).
OST
The marker substances for OST were determined to
be methadone, levomethadone, buprenorphine and
buprenorphine/naloxone. The determined DDD were
90 mg for methadone, 45 mg for levomethadone, and
8 mg for buprenorphine and buprenorphine/naloxone
(Table 1).
Results
By June 2014, of the total 16 German FS, the MoJ of the
12 FS Bavaria, Berlin, Bremen, Hamburg, Mecklenburg-
Western Pomerania, Lower Saxony, Rhineland Palatinate,
Saarland, Saxony, Saxony-Anhalt, Schleswig-Holstein and
Thuringia had agreed to the study. Rhineland Palatinate
could not deliver the data and was excluded. In the study
period the 11 participating FS with 34,191 prisoners in 97
prisons represented almost half of all German prisoners
(N = 67,607) in 186 prisons (Fig. 3).
Detailed results for each disease and FS are shown in
Table 2.
TB treatment
About 41% of the 97 prisons were supplied with medicines
against TB. There was no TB medicine supply at all to
prisons in Saarland. Both marker substances E and Z for
the intensive phase were delivered to all investigated FS























































March 2012 Aug. 2012 Nov. 2012 March 2013 average per month
Fig. 2 Average number of prisoners per month in the respective FS and in total during the study period January 2012 and March 2013. Bavaria
(BY), Berlin (BE), Bremen (HB), Hamburg (HH), Mecklenburg-Western Pomerania (MV), Lower Saxony (NI), Saarland (SL), Saxony (SN), Saxony-Anhalt
(ST), Schleswig-Holstein (SH) and Thuringia (TH)
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Fig. 3 Participation in the study and number of prisons in the respective FS of Germany
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except for Mecklenburg-Western Pomerania, Schleswig-
Holstein and Thuringia. Both marker substances H and R
for the continuation phase and chemoprevention were
supplied to all FS except Thuringia. Mecklenburg-
Western Pomerania and Schleswig-Holstein only received
the marker substances H and R, Thuringia only the sub-
stances E and H. Substances for the treatment of drug
resistant or complicated or severe TB were provided in
the FS Bavaria, Berlin and Thuringia.
The adTP of E and Z in the initial stage ranged from
0% in Mecklenburg-Western Pomerania, Saarland,
Schleswig-Holstein and Thuringia (Z) to 0.16% (E) and
0.15% (Z) in Hamburg. The adTP of H and R in the
continuity stage ranged from 0% in Saarland and Thur-
ingia (R) to 0.26% in Saxony-Anhalt (H) and 0.22% in
Hamburg (R). In total, twice as many delivered marker
substances were indicated for the continuation phase
and chemoprevention than the intensive phase (H & R:
0.09% & 0.07% vs. E & Z: 0.04% & 0.03%). The formula-
tion 400 mg isoniazid per pill played only a marginal
role in Lower-Saxony, Saxony-Anhalt and Schleswig-
Holstein. Pto as a marker substance for MDR-TB treat-
ment was only delivered in Berlin (adTP 0.01%). Trd
also as a marker substance for MDR-TB was delivered in
Bavaria (adTP 0.01%) and Berlin (adTP 0.02%). Rfb as
marker substance for the TB treatment of patients with
HIV-TB-coinfection was delivered in Bavaria (adTP
0.01%) and Thuringia (adTP 0.02%).
HIV treatment
Overall, 71% of the included prisons in the respective FS
were delivered with drugs for HIV treatment. HIV DDDcum
ranged from 510 in Thuringia to 18.900 in Bavaria. HIV
DDDd ranged from 1 in Thuringia to 41 in Bavaria. HIV
adTP ranged from 0.06% in Saxony to 0.94% in Bremen.
The overall HIV adTP was 0.39%.
Nucleoside reverse transcriptase inhibitor (NRTI) sub-
stances and protease inhibitor (PI) substances were
supplied to all participating FS. With the exception of
Thuringia, all other FS were supplied with non-nucleoside
reverse transcriptase inhibitor (NNRTI) substances and the
integrase inhibitor (INI) raltegravir. The entry inhibitor
(EI) maraviroc was supplied exclusively to Bavaria and
Berlin.
HCV treatment
In total, 58% of the represented prisons were delivered
with drugs for HCV treatment. In the FS of Bremen and
Saxony-Anhalt, all prisons were supplied with HCV drugs.
HCV DDDcum ranged from 182 in Mecklenburg-Western
Pomerania to 4.116 in Bavaria. HCV DDDd ranged from 0
in Mecklenburg-Western Pomerania to 9 in Bavaria. HCV
adTP ranged from 0.03% in Mecklenburg-Western Pom-
erania to 0.59% in Bremen. The overall HCV adTP was
0.12%. BOC DDDcum ranged from 0 in seven FS to 245 in
Saxony. BOC DDDd ranged from 0 in seven FS to 1 in
Saxony. BOC adTP ranged from 0% in seven FS to 0.02%
in Bremen. TVR DDDcum ranged from 0 in five FS to 455
in Lower-Saxony. TVR DDDd ranged from 0 in five FS to
1 in Lower-Saxony. TVR adTP ranged from 0% in five FS
to 0.02% in Lower-Saxony.
OST
Regarding opioid substitutions, 58% of the included
prisons in the respective FS were supplied with drugs for
OST. OST DDDcum ranged from 0 in Saarland to
151.684 in Lower-Saxony. OST DDDd ranged from 0 in
Saarland to 333 in Lower-Saxony. OST adTP ranged
between 0% in Saarland and 7.90% in Bremen. The over-
all OST adTP was 2.18%.
Discussion
The results show that medical treatment of all investi-
gated diseases took place in German penal institutions.
However, under the assumption that the number of
adTP corresponds to the number of treated people per
day, differences in quantity and extent of treatment were
observed among the FS. To what extent requirements
and directives of the MoJ affect the initiation of treat-
ment and health care seems to differ not only among FS
but also among prisons within the FS [35, 42, 43]. The
differences regarding treatment of diseases and OST in
prisons might reflect the decentralized federal system in
Germany, in which the states may pursue different
approaches with respect to the management of medical
care [5, 6, 39].
TB treatment
Our data suggests intensive and continued tuberculosis
treatments as well as chemoprevention in prisons of all
participating FS except Saarland, where no TB medicine
supply was observed. The treatment of resistant, compli-
cated or severe TB was carried out in the FS Bavaria, Berlin
and Thuringia. The federal city-states Berlin, Bremen and
Hamburg showed high treatment prevalences for all TB
substances, which implies largely initiated and continued
TB treatment in those penal institutions. In Mecklenburg-
Western Pomerania, Saarland and Schleswig-Holstein TB
treatment was not initiated since these FS were not sup-
plied with E and Z. However, Mecklenburg-Western
Pomerania, Lower-Saxony, Saxony-Anhalt and Schleswig-
Holstein showed high adTP of H and R which suggest
mostly continued TB treatment and chemoprevention. In
addition, Thuringia showed solely high H adTP, which
might also indicate chemoprevention. A further indication
of H is the treatment of R-resistant TB. However, since the
proportion of corresponding E and Z is too low in the
respective FS this may play only a marginal role [26].
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Further, we observed a ratio of the marker substances for
the intensive and continuation phase that might indicate in-
complete standard six-month regimen in most FS.
However, since imprisonment can begin or end during the
course of a treatment, our observation period did not
necessarily capture the entire treatment time.
In all penal institutions in Berlin, each newly incarcer-
ated person is screened for TB by chest x-ray [24]. This
active case-finding when entering prison can be equated
with the prevalence of TB at the time of imprisonment
[24]. Bös and Hauer found a TB prevalence of 0.11%
through active case-finding by chest x-ray examinations
in 2007–2010 in Berlin’s penal institutions and 0.21% in
1996–1998 [24, 44]. Our work found an adTP in Berlin
of 0.08% and 0.10% for the marker substances E and Z,
respectively. Comparing the most recent TB prevalence
seen in Berlin’s penal institutions to the adTP from our
analysis, treatment rates for TB were at least in Berlin
consistent with the expected TB prevalence. The most
important reason for not treating a prisoner in the study
by Bös et al. was a too short duration of imprisonment
[24]. We found an almost equal distribution of the adTP
for H and R possibly explained by the active case-finding
in Berlin with no need for chemoprevention.
Treatment of Multidrug-Resistant-TB and of compli-
cated or severe TB were each observed in only two FS,
Berlin and Bavaria and Thuringia and Bavaria, respect-
ively. This was possibly due to a transfer of patients to
prison hospitals with necessary existing technical and
logistical conditions.
The large range of the provision of drugs for TB treat-
ment among the FS could be explained by co-operations
between FS. Especially the co-operation of Saarland with
Bavaria and North Rhine-Westphalia might be the reason
why there was no TB treatments at all supplied to prisons
in Saarland. According to this arrangement Saarland
transferred TB infected male prisoners to Bavaria and TB
infected female prisoners to North Rhine-Westphalia for
treatment. Also Thuringia had a co-operation with Bavaria
and transferred TB infected prisoners to Bavaria. However,
TB treatments were still carried out in Thuringia with H,
E and Rfb, and the latter is indicated for HIV-TB-
coinfected patients. We speculate the reason why TB
treatments were still carried out in Thuringia despite
existing co-operations could be overcrowding or other
factors that would need further investigation.
HIV treatment
HIV treatments were carried out in prisons of all partici-
pating FS, with highest treatment prevalences found in
the federal city-states Bremen, Hamburg and Berlin. The
higher HIV adTP compared to the HCV adTP is remark-
able, especially considering that studies found a much
lower HIV prevalence compared to the HCV prevalence
among prisoners. Radun et al. found an HIV antibody
prevalence of 0.7% [3]. Schulte et al. came to an HIV
prevalence of 1.2%. In this study, 147 prisoners were
treated against HIV per year corresponding to 1.0% of
all represented prisoners and to 89% of the infected pris-
oners [5]. In a study by Reimer et al., 300 prisoners were
treated corresponding to about 1.0% of the represented
prisoners and to about 94% of the infected prisoners
[39]. Our results are in accordance with these previous
studies, and the treatment prevalence of 0.39% for HIV
matches more or less the expected prevalence of infec-
tion. HIV treatment seems to be the only of the four
investigated treatments that is offered to an adequate
proportion of estimated infected prisoners.
The combination of the agents and drug classes sug-
gest treatment according to treatment guidelines which
recommend a combination of two NRTI with either a
NNRTI, PI or INI for first line therapy. The proportion
of NRTI DDDcum to total NNRTI, PI and INI DDDcum
suggests standard regimen distribution. Additionally,
within the drug classes the DDDcum of the drugs corres-
pond to a standard regimen. Substances differing from
the standard therapy were rarely administered. This
applies, for example, to the older NRTI substance dida-
nosin and the nowadays less frequent PI substance
fosamprenavir. On the other hand, newer substances
were also prescribed rather infrequently, which could
indicate a hesitation to apply them. This is clearly seen
in rilpivirin in the substance group of the NNRTI.
Furthermore, we found indication for continuation and
switch of ART of previously treated prisoners. This can
be seen through the delivery of etravirin in Bavaria,
Hamburg and Saarland, which is indicated for the treat-
ment in antiretroviral treatment-experienced patients.
HCV treatment
Our data suggest that HCV treatments were provided in
prisons of all participating FS. Overall, during the obser-
vation period, only 0.12% of prisoners were treated per
day with HCV antivirals. This HCV treatment preva-
lence appears to be too low considering that studies have
shown HCV prevalences to be about 14% to 21% among
prisoners [3, 5, 39]. In the comparison of the FS, Bremen
showed the highest HCV treatment prevalence, followed
by Saarland and Schleswig-Holstein. In the two other
federal city-states Berlin and Hamburg very low HCV
treatment prevalences were observed, which is not con-
sistent with the high HIV treatment prevalence in both
cities. The one third lower adTP in Berlin compared to
the overall adTP was therefore surprising considering
Berlin has the highest incidence of newly diagnosed
HCV of all FS [45], and risk group populations are dis-
proportionately present. We assume that the prevalence
of HCV and the need of treatment among prisoners differ
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from prison to prison depending on the proportion of pris-
oners from FS with higher HCV prevalence, the proportion
of PWID among prisoners, as well as the proportion of
prisoners originating from countries with high HCV preva-
lence. Also, intra- and extramural co-operations among FS
may at least partially explain the different treatment preva-
lences [46]. Although studies found a much higher HCV
prevalence than HIV prevalence among prisoners [3, 5, 39]
the amount of HCV treatment per prisoner is much lower
than of HIV treatment.
Furthermore, the observed HCV treatment prevalence
in view of the high HCV antibody prevalence of 20.6%,
14.3% and 15.0% found among prisoners in surveys is
much too low [3, 5, 39]. These studies in German prisons
found low HCV treatment rates and support our findings,
only 111 (0.8% of the represented prisoners) and 400
(1.4% of the represented prisoners) prisoners were treated
per year [5, 39]. According to Schulte et al., the main
exclusion criteria for HCV treatment were short duration
of imprisonment and drug abuse [5]. Also in comparison
to the prevalence of injecting drug use (IDU) by
Radun et al. (29.7%) and Schulte et al. (21.9%), the
HCV adTP of 0.12% appeared to be too low consider-
ing that studies have shown HCV antibody prevalences
of 57.6% among PWID [3, 5, 27]. Furthermore accord-
ing to current guidelines, IDU is no contraindication
for HCV therapy [27].
At the time of the analysis, HCV was treated in particu-
lar with a dual combination of PEG-IFN and RBV accord-
ing to the respective guidelines at that time. There was
also the option of a triple therapy with one of the two
protease inhibitors BOC or TVR in combination with
PEG-IFN and RBV. However, this treatment was cost ex-
tensive and rich in side effects and assumedly therefore
played virtually no role for the HCV treatment in prisons.
Triple therapies containing BOC or TVR accounted for
only 7.8% of all HCV treatments. Sligthly more triple ther-
apies were observed in Berlin and about two times more
in Bremen, Lower Saxony and Saxony. In 2013, new
promising direct-acting antivirals (DAAs) against HCV
had already been announced. It is possible that the low
treatment numbers are partially related to the awaiting of
upcoming treatment options as an analysis of drug
prescription data of the general German population also
suggests [47]. Furthermore, due to the relative ineffect-
iveness and often serious side effects of interferon-
based treatment, it seems plausible that prisoners are
even less likely to wish to undergo debilitating treat-
ment than non-prisoners. However, it is unknown to
what extent costly DAA regimens have been prescribed
since 2014 in the prison setting. An investigation of
that would be a valuable follow-up assessment of the
extent and quality of medical treatment in German
prisons.
OST
We found a large range of the OST adTP between 0% in
Saarland and 7.9% in Bremen. Thus, in some FS OST
seems to be provided to a high proportion of prisoners,
indicating a more liberal and harm-reduction-led politic.
In the northern FS more prisoners had access to OST
compared to Saarland and Bavaria and the eastern FS
[46]. None of the prisons in Saarland and only seven
penal institutions in Bavaria were supplied with OST
medicines. The amount of OST doses suggests therapy
in the northern FS and an abstinence and denial
approach in Saarland, Bavaria and the eastern FS. This
imbalance and therapy slope among the FS was already
described by Keppler et al. [33, 46].
The low number of OST-supplied penal institutions in
Bavaria is remarkable. Although OST needs no special
medical tools or rooms and is simple to carry out only 7
of the 36 prisons were supplied with OST substances in
Bavaria, corresponding to an OST adTP of 0.06%. Due
to this low OST adTP, we assume a practice of denial or
withdrawal rather than substitution treatments offered
to prisoners in Bavaria [48]. The number of 133 DDDd
OST we found in Berlin correlates well with the number
of 154 and 120 OST reported for Berlin prisons by Kep-
pler in Lehmann et al. [46] and by Jakob et al. [35]. Ac-
cording to this, 3.6% of the prisoners in Berlin received
OST compared to 3.2% in our study [46]. Schulte et al.
accounted for 1,137 OST per year altogether, which cor-
responds to 8.0% of the represented prisoners and to
37% of the PWID in prison [5]. In Reimer’s work, 320
long time opioid substitutions correspond to about 1.1%
of the represented prisoners [39]. The overall OST adTP
of 2.18% we found in our study approximately matches
the OST treatment prevalence of Schulte et al. and
Reimer. However, given the IDU prevalence of 29.7%
and 21.9% among prisoners found in other studies [3, 5],
even in the FS with a comparably high OST prevalence
it can be concluded that only a minority of prisoners in
need receive OST. Reporting on the prevalence of opioid
dependence among people in prison was recently imple-
mented in Germany, but the data is not yet published. It
might be assumed that IDU mostly consists of opioid
consumption. It is possible that some people coming
into prison want to use the opportunity to be treated
and to stop injecting but that others might prefer a cold
withdrawal or do not want to reveal their addiction to
avoid stigmatization or disadvantages concerning their
prison conditions. Nonetheless our data show a need for
scaling up OST, at least in some of the FS.
About 25% of the male and 50% of the female pris-
oners in Germany are PWID [33]. OST provided during
incarceration reduces the level of IDU in prison and thus
the possibility of HIV and HCV transmission via unsafe
use [49]. OST as an approved effective therapy functions
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well in a prison setting, e.g. supervised application, regu-
larity of intake and structured daily life [33]. OST,
particularly in combination with other harm-reduction
strategies, is an evidence-based measure of HIV and
HCV prevention [16, 50, 51]. In addition, people who
receive OST often show an increased compliance re-
garding antiviral and antiretroviral treatment [52, 53].
For the above mentioned reasons and its protective
effects, it is incomprehensible that OST is not offered in
every prison. According to information provided by
several prison doctors a certain proportion of PWID and
thus, people in potential need of OST, are among every
prison population, and no distribution of PWID to
special prisons takes place. Further, this would not
explain the high range of OST among the FS, suggesting
an abstinence-oriented and denial approach in some FS.
IDU in prison is often unsafe due to the unavailability
of sterile materials and is therefore one of the main
transmission routes and major risks for HCV. Studies
have shown an HCV antibody prevalence of 57.6%
among PWID [3] therefore, the HCV adTP of 0.12% ap-
peared to be too low compared to the OST adTP of
2.18%. Studies revealed that OST access depended
mainly on substitution treatment before imprisonment,
short duration of imprisonment and co-morbidity such
as infectious diseases [5, 42].
Although OST guidelines exist for Germany [54], this
work shows that these guidelines are not consistently
applied, and that intramural OST highly differs among the
FS and prisons. This might be due to the lack of nation-
wide OST guidelines for prisons [35]. However, in the
absence of prison-specific guidelines the existing national
OST guidelines should be applied to prisoners as well.
Limitations
The following limitations have to be considered in the
interpretation of the data.
The evaluation of pharmacy delivery data allows no
statement about which and how many medicines actu-
ally reached the individual patient. This can potentially
lead to an overestimation of the calculated DDD for all
evaluated drugs because they can be ordered in advance.
On the other hand, emergency or ad hoc-orders are
taken over by local pharmacies not included in our ana-
lysis, leading to a potential underestimation of the data
and the corresponding treatments. However, according
to a prison-supplying pharmacy, emergency orders
amount to less than 2% [55]. Furthermore, one drug
package might be used for several patients. Usually, the
pills are packaged according to the prescription per pa-
tient or per patient and day [56]. We tried to avoid a
bias by calculating the treatment prevalence per day.
Tablets are divided only in particular cases. However,
this procedure can differ from prison to prison. In
addition, there are differences in the treatment manage-
ment and the supply of medication in case of transfers
of prisoners. In some cases, medicines are completely
provided by the previously responsible prison. In other
cases, after the transfer to another prison, the medicines
are provided by the new prison [56].
The treatment success and failure, including side ef-
fects and drug interactions, remain unknown. We had
no knowledge of the treatment duration. Therefore we
calculated the average treatment prevalence as point
prevalence in percent at each single day of the whole
study period. For OST we did not consider initial dosage
or gradual reduction of OST, but assumed a steady dos-
age, so we might have underestimated the number of
persons under OST medication.
Because of the missing pharmacy data of one sick ward
in a prison in Mecklenburg-Western Pomerania with five
beds and one correctional hospital in Lower Saxony with
52 beds, the data of Mecklenburg-Western Pomerania
and Lower Saxony are not complete. Therefore the DDD
and adTP in these FS might be underestimated.
Several co-operations exist among the FS limiting the
representativeness of the data for the respective FS. For
example, Saarland had a contract to transfer ill prisoners
to Rhineland-Palatinate [36]. Schleswig-Holstein had a
transfer co-operation with Hamburg [37]. Thuringia had
co-operations with Saxony, Saxony-Anhalt and Hessen
to transfer ill prisoners [38]. Therefore the DDD and
adTP of Saarland, Schleswig-Holstein and Thuringia are
potentially underestimated and of Hamburg, Saxony and
Saxony-Anhalt are potentially overestimated.
A further limitation is the different temporal units of
the pharmacy delivery data on the one hand (per quarter
of a year) and the number of the prisoners on the other
hand (four calendar months). The actual duration of im-
prisonment as well as the information on releases such
as the day of the release and the number of released
prisoners cannot be derived from the available data and
remain unknown. Therefore we chose to account the
DDD for each day in the study period.
Moreover, this paper describes merely the proportion
of treated persons among all prisoners and not among
infected prisoners. To evaluate our treatment preva-
lence, we compared it with the prevalence seen in previ-
ous studies.
Conclusions
This work is the first attempt to describe and assess the
medical care of TB, blood-borne and sexually transmitted
infections and OST in prison. The study indicates that
treatment of TB, HCV, HIV and opioid dependence is car-
ried out in German penal institutions, and that guideline-
recommended substances and standard treatments are
used. However, a high variation of treatment per prison
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population was observed among the FS and among the
respective diseases, which is not fully explained by the
described transfer co-operations. Providing treatment of
chronic infections and OST to prisoners seems to be
dependent on structural and individual factors, e.g. the
prison’s medical service structure, the political attitude
and the allocation of financial budget to medical treatment
in the respective prison and in the FS. The WHO recom-
mendations and the UN’s Mandela Rules maintain that
prisoner health care should be consistent with the com-
munity standards of care, and under the direction of the
ministry of health [57]. According to our findings, prison
health care and policy in Germany is not fully consistent
with this, especially with regard to treatment of HCV and
OST. Treatment rates for TB were consistent with the ex-
pected TB prevalence, at least in Berlin. Treatment for
HIV seems to be the one that is offered to a more or less
adequate proportion of estimated infected prisoners in the
FS. In the view of the expected high HCV prevalence
among prison populations and in comparison to HIV and
opioid dependence treatment prevalence, the HCV treat-
ment prevalence we observed was too low. HCV treat-
ment with DAAs has improved remarkably since the
study period and will hopefully have an impact on the
treatment prevalence in prisons despite high costs.
Despite a varying proportion of PWID among prisoners
and limitations due to a purely secondary data analysis,
the large differences among the FS regarding all infection
treatments and OST point to inconsistent treatment prac-
tices although nationwide extramural treatment guidelines
for Germany exist. It is alarming that some FS seem to
provide OST at a very low level. However, in some FS our
data suggest that a high proportion of prisoners is covered
with OST.
Despite its challenges, the prison setting is an oppor-
tunity for prevention and treatment of TB, HIV, HCV
and OST [18] which could be carried out at a greater
extent and more consistently. The regulated environ-
ment offers good requirements for e.g. distribution of
sterile injection utensils, supervised application, regu-
larity of intake and the opportunity for restructuring
of daily life. Prisons therefore provide both risks for
the spread of diseases but also many opportunities for
prevention of these infections [17]. Continuous ana-
lyses for longer periods are necessary in order to make
further statements regarding the health care situation
in German prisons. A monitoring and reporting system
of infectious diseases among prisoners would help to
ensure equal access to treatment and to harmonize
strategies among FS. Finally, correctional facilities
should consistently implement prevention and harm-
reduction measures such as needle-exchange and con-
dom distribution programs to avoid further spread of
diseases [30].
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